Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
OSARO and Geek+ Partner to Integrate Robotic Warehouse Solutions
Euna Solutions Appoints Industry Veteran Tom Amburgey as Chief Executive Officer
Employee data leaked during British Library cyber attack
MrBeast breaks own YouTube views record by 'outperforming' 'Squid Game' video in just 24 hours
MosaicML Releases Open-Source MPT-30B LLMs, Trained on H100s to Power Generative AI Applications
GPU tech supplier Imagination Technologies lays off 20% of staff -sources
Zoom Talked With Regulators About Microsoft Competition Concerns
Frontgrade and Lattice Collaboration Produces First Low SWAP-C FPGA